Kelly said until the company sheds more light on the experimental products it intends to bring out next year it will be difficult to accurately assess the 2002 outlook.
"What we have is they suspect Bristol-Myers has something that may result in causing analysts to do downgrades," Coxe said. "I'm going to be intrigued about what they say next week. If they don't say something, I'll be even more perplexed."
RSS